Mauna Kea Technologies (Mauna Kea Technologies) ROCE % : 138.47% (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mauna Kea Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mauna Kea Technologies's annualized ROCE % for the quarter that ended in Jun. 2023 was 138.47%.

Mauna Kea Technologies ROCE % Historical Data

The historical data trend for Mauna Kea Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mauna Kea Technologies ROCE % Chart

Mauna Kea Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-62.44

-93.84

-87.86

-81.68

-85.01

Mauna Kea Technologies Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-418.80	-307.75	-84.15	-106.05	138.47

Mauna Kea Technologies ROCE % Calculation

Mauna Kea Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-11.574	/	( ( (27.967 - 8.293)	+	(20.967 - 13.411) )	/ 2 )
	=	-11.574	/	( (19.674	+	7.556)	/ 2 )
	=	-11.574	/	13.615
	=	-85.01 %

Mauna Kea Technologies's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	12.784	/	( ( (20.967 - 13.411)	+	(26.263 - 15.355) )	/ 2 )
	=	12.784	/	( ( 7.556	+	10.908 )	/ 2 )
	=	12.784	/	9.232
	=	138.47 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Mauna Kea Technologies (OTCPK:MKEAF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mauna Kea Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Mauna Kea Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mauna Kea Technologies (Mauna Kea Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Mauna Kea Technologies SA (OTCPK:MKEAF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALMKT:France 1MK:Germany

Address

9, rue d'Enghien, Paris, FRA, 75010

Website

https://www.maunakeatech.com

Mauna Kea Technologies SA is a medical device corporation. It is engaged in designing, developing, and marketing an imaging platform used to view tissues at a cellular level, in real-time, during standard procedures. The firm operates in the business segment of Endomicroscopy. The group's technological platform is Cellvizio which helps physicians to detect early-stage pathologies more accurately and make therapeutic decisions. It generates revenue from the sales of Cellvizio products and accessories used for medical diagnostics, research, and related services. The company sells its products in France and internationally, of which the majority of the revenue is derived from America.

Mauna Kea Technologies (Mauna Kea Technologies) Headlines

From GuruFocus

Q1 2022 Mauna Kea Technologies SAS Earnings Call Transcript

By GuruFocus Research • 03-01-2024

Q4 2020 Mauna Kea Technologies SAS Earnings and Q1 2021 Sales Release Transcript

By GuruFocus Research • 03-01-2024